Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067730 · ClinicalTrials.gov registry record · Phase 4
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00067730 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7 participants.
The verdict
NCT00067730, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for bone marrow transplant (BMT).
Interventions
- DRUG Drotrecogin Alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2003-03 |
| Est. Completion | 2003-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067730
The ClinicalTrials.gov registry entry for NCT00067730 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drotrecogin Alfa (activated) is the first listed.
NCT00067730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067730 about?
NCT00067730 is a clinical study titled "A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation". The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for bone marrow transplant (BMT).
What is the current status of trial NCT00067730?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2003-03. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00067730?
The interventions under investigation include: Drotrecogin Alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00067730?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.